Rebecca Jones is vice president of medical services at Imagen Technologies and clinical assistant professor of neuroscience in psychiatry at Weill Cornell Medicine in New York City.
Rebecca Jones
Vice president of medical services
Imagen Technologies
From this contributor
Review: ‘Uncommon Sense’ exquisitely explores autism’s sensory experiences
The play dexterously depicts the struggles — sensory and social — of four characters who occupy distinct places on the autism spectrum.
Review: ‘Uncommon Sense’ exquisitely explores autism’s sensory experiences
By
Rebecca Jones
5 December 2017 | 6 min read
Explore more from The Transmitter
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
By
Ashley Juavinett
30 March 2026 | 8 min read
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
By
Dalmeet Singh Chawla
27 March 2026 | 5 min read
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
By
Claudia López Lloreda
26 March 2026 | 4 min read